Advertisement

Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy

Published:February 02, 2022DOI:https://doi.org/10.1016/j.brachy.2022.01.001

      Abstract

      BACKGROUND AND PURPOSE

      To determine the factors associated with a positive post-treatment prostate biopsy (PB) and the effects of local failure on biochemical control and cause-specific survival (CSS) in men receiving prostate brachytherapy.

      METHODS AND MATERIALS

      Of 545 men with post-implant PB, 484 were routine (median 24 months) while 61 (median 55 months) were for cause. 114 had a repeat PB for rising PSA. Initial mean PSA was 10.5 ng/ml (±13.9) while 244 (44.8%), 202 (37.1%) and 99 (18.2%) had low, intermediate or high-risk disease. Treatments were implant only in 287 (52.7%), and implant with androgen deprivation therapy (ADT) ± external beam in 258. Radiation doses were converted to the biologically equivalent dose (BED). Final biopsy results were the last biopsy performed on that patient. Associations for the first and final biopsies with PSA, clinical stage (CS), Gleason grade group, time on hormone therapy (ADT) and BED were determined by ANOVA, chi-square and binary linear regression. Freedom from Phoenix failure (FFPF) and cause-specific survival were estimated by Kaplan Meier method and Cox proportions hazards.

      RESULTS

      After a median of 11.4 years the first and final biopsy were positive in 10.8% and 8.8%, respectively. Significant linear regression associations with first positive PB were ADT (p = 0.005), CS (p = 0.044) and BED (p = 0.030) while only BED (p < 0.001) was significant for the final PB. Positive biopsy occurred in 21/112 (18.8%), 16/230 (7.0%) and 3/182 (1.6%) for BED ≤150, >150–200 and >200 Gy (p < 0.001), and in 29/261 (11.1%) for BED (median) ≤185 Gy vs. 5/263 (1.9%) for > 185 Gy (OR 4.2, p < 0.001). 15-year FFPF was 75.6 vs. 17.5% and cause-specific survival was 94.2 vs. 75.5% for negative vs. positive biopsy.

      CONCLUSIONS

      Higher radiation doses are associated with 1.9% late local failure following prostate brachytherapy. A negative post-implant PB is associated with superior FFPF and decreased prostate cancer mortality.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Swanson G.P.
        • Hussey M.A.
        • Tangen C.M.
        • et al.
        Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.
        J Clin Oncol. 2007; 25: 2225-2229https://doi.org/10.1200/JCO.2006.09.6495
        • Zapatero A.
        • Mínguez R.
        • Nieto A.
        • et al.
        Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?.
        Eur. Urol. 2009; 55: 902-910https://doi.org/10.1016/j.eururo.2008.04.076
        • Zapatero A.
        • Adrados M.
        • Torres A.
        • et al.
        Positive prostate biopsy following radiotherapy can predict metastasis-free survival in localized prostate cancer.
        Rep Pract Oncol Radiother. 2020; 25: 55-59https://doi.org/10.1016/j.rpor.2019.12.003
        • Crook J.
        • Malone S.
        • Perry G.
        • et al.
        Postradiotherapy prostate biopsies: what do they really mean? results for 498 patients.
        Int J Rad Oncol Biol Phys. 2000; 48: 355-367https://doi.org/10.1016/S0360-3016(00)00637-4
        • Stone N.N.
        • Stock R.G.
        • White I.
        • et al.
        Patterns of local failure following prostate brachytherapy.
        J Urol. 2007; 177: 1759-1764https://doi.org/10.1016/j.juro.2007.01.069
        • Thompson I.M.
        • Tangen C.M.
        • Paradelo J.
        • et al.
        Adjuvant radiotherapy for locally advanced prostate cancer: results of a randomized, prospective clinical trial.
        JAMA. 2006; 296: 2329-2330https://doi.org/10.1001/jama.296.19.2329
        • Bolla M.
        • van Poppel H.
        • Collette L.
        • et al.
        Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911).
        Lancet. 2005; 366: 572-578https://doi.org/10.1016/S0140-6736(05)67101-2
        • Kass-Iliyya A.
        • Jovic G.
        • Murphy C.
        • et al.
        Two-years postradiotherapy biopsies: lessons from MRC RT01 Trial.
        Eur Urol. 2018; 73: 968-976https://doi.org/10.1016/j.eururo.2017.12.017
        • Zelefsky M.J.
        • Fuks Z.
        • Hunt M.
        • et al.
        High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
        J Urol. 2001; 166: 876-881https://doi.org/10.1016/S0022-5347(05)65855-7
        • Stock R.G.
        • Stone N.N.
        • Cesaretti J.
        • et al.
        Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsies.
        Int J Rad Oncol Biol Phys. 2006; 64: 527-533https://doi.org/10.1016/j.ijrobp.2005.07.981
        • Stone N.N.
        • Stock R.G.
        • Cesaretti J.A.
        • et al.
        Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes.
        Int J Rad Oncol Biol Phys. 2010; 76: 335-360https://doi.org/10.1016/j.ijrobp.2009.01.078
        • Stone N.N.
        • Unger P.
        • Crawford E.D.
        • et al.
        Diagnosis and management of local recurrence after low-dose-rate brachytherapy.
        Brachytherapy. 2015; 14: 124-130https://doi.org/10.1016/j.brachy.2014.08.046
        • Xiao G.Q.
        • Huan Y.
        • Stone N.
        • et al.
        Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapy.
        Pathol Res Pract. 2009; 205: 843-846https://doi.org/10.1016/j.prp.2009.07.009
        • Murphy A.M.
        • Berkman D.S.
        • Desai M.
        • et al.
        The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy.
        BJUI. 2010; 105: 176-179https://doi.org/10.1111/j.1464-410X.2009.08707.x
        • Zumsteg Z.S.
        • Spratt D.E.
        • Romesser P.B.
        • et al.
        Anatomic patterns of recurrence following biochemical relapse in the dose-escalation era for prostate patients undergoing external beam radiotherapy.
        J Urol. 2015; 194: 1624-1630https://doi.org/10.1016/j.juro.2015.06.100
        • Solberg A.
        • Haugen O.A.
        • Viset T.
        • et al.
        Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
        Int J Rad Oncol Biol Phys. 2011; 80: 55-61https://doi.org/10.1016/j.ijrobp.2010.01.072
        • Crehange G.
        • Krishnamurthy D.
        • Cunha J.A.
        • et al.
        Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy.
        Radiother Oncol. 2013; 109: 246-250https://doi.org/10.1016/j.radonc.2013.10.028
        • Stone N.N.
        • Unger P.
        • Crawford E.D.
        • et al.
        Diagnosis and management of local recurrence after low-dose-rate brachytherapy.
        Brachytherapy. 2015; 14: 124-130https://doi.org/10.1016/j.brachy.2014.08.046
        • Morris W.J.
        • Tyldesley S.
        • Rodda S.
        • et al.
        Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
        Int J Rad Oncol Biol Phys. 2017; 98: 275-283
        • Joseph D.
        • Denham J.W.
        • Steigler A.
        • et al.
        Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial.
        Int J Rad Oncol Biol Phys. 2020; 106: 693-702
        • Kanthabalan A.
        • Arya M.
        • Freeman A.
        • et al.
        Intraprostatic cancer recurrence following radical radiotherapy on transperineal template mapping biopsy: implications for focal ablative salvage therapy.
        J Urol. 2020; 204: 950-955
        • Stock R.G.
        • Stone N.N.
        • Cessaretti J.
        • et al.
        Prostate specific antigen bounce following prostate seed implantation for localized prostate cancer: descriptions and implications.
        Int J Rad Oncol Biol Phys. 2003; 56: 448-453https://doi.org/10.1016/s0360-3016(02)04470-x
        • Stone N.N.
        • Crawford E.D.
        • Skouteris V.M.
        • et al.
        The ratio of the number of biopsy specimens to prostate volume (biopsy density) >1.5 improves the prostate cancer detection rate in men undergoing transperineal biopsy of the prostate.
        J Urol. 2019; 202: 264-271https://doi.org/10.1097/JU.0000000000000204